Blood
Articles in this Issue
Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera
Abstract Polycythemia vera (PV), a BCR::ABL1-negative myeloproliferative neoplasm characterized by erythrocytosis and commonly associated wi...
Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL
Abstract Background: High tumor burden is associated with poor outcomes in CAR-T cell therapy. Although radiotherapy and chemotherapy are co...
Characterization of children and adolescents with Acute Myeloid Leukemia potentially treatable with menin inhibitors
Abstract Background Children with leukemia should have timely access to effective therapies. In pediatric acute myeloid...
Incidence and diagnosis of iron deficiency among patients receiving a blood transfusion in the emergency department
Abstract Background Iron deficiency anemia (IDA) is the most common nutritional disorder worldwide and a leading cause of anemia in the Unit...
Foreign antigen delivered to CLL B cells via membrane IgD leads to a distinct antigen processing pathway that allows antigen-specific T cell activation that is superior to membrane IgM delivery
Abstract Introduction Effective T-cell-dependent immune responses are initiated by the uptake of antigen by antigen presenting cells (APCs) t...
Optim.AI™ 2.0: Functional precision platform for identifying effective immunotherapy combinations in DLBCL
Abstract Introduction: Immunotherapies have significantly advanced the treatment of diffuse large B-cell lymphoma (DLBCL), particularly thro...
Ofirnoflast, a novel inflammasome inhibitor, rewires transcriptional programs and shows clinical and preclinical efficacy in myeloid neoplasms
Abstract Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are inflammatory myeloid neoplasms marked by ineffective...
Patient characteristics, treatment patterns, and bleeding in people with Hemophilia A without inhibitors initiating efanesoctocog alfa in the US: An administrative claims analysis
Abstract Background: Hemophilia A is a rare genetic disorder causing spontaneous bleeding and joint damage. Efanesoctocog alfa (Efa) is a fi...
Oral Care™ kit as a prophylaxis for talquetamab-associated toxicities in patients with Relapsed/Refractory multiple myeloma
Abstract Background: Talquetamab, a GPRC5D×CD3 bispecific antibody, has shown promising efficacy in relapsed/refractory multiple myeloma (RR...
Nelarabine treatment before allogeneic stem cell transplantation was associated with an increased risk of neurological adverse events in patients with T-ALL/lbl: A retrospective study of the kanto study group for cell therapy.
Abstract [Introduction] Nelarabine (NEL) is an agent approved specifically for T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lympho...
Germline genetic variants and post-HCT cytokine/chemokine milieu may identify those at higher risk of primary graft failure after allogeneic hematopoietic cell transplantation, a blood and marrow transplant clinical trials network (BMT CTN) study
Abstract Introduction: Primary graft failure (PGF) after hematopoietic cell transplant is a life-threatening complication due to the absence...
Hematologic adverse events associated with immune checkpoint inhibitors: A real-world pharmacovigilance analysis using the faers database
Abstract Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancers. With their increased use and prolonge...
Menin inhibitors for NPM1-mutated and KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML): A systematic review and meta-analysis
Abstract Background: Approximately one-third of adult AML cases are characterized by mutations in nucleophosmin 1 (NPM1), which encodes a pr...
Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience
Abstract Introduction: Mantle cell lymphoma (MCL) is usually an incurable lymphoma with no standard frontline therapy. Increasingly, Bruton...
Teclisito: Low-intensity teclistamab in the outpatient setting for Relapsed/Refractory multiple myeloma
Abstract Introduction Bispecific antibodies targeting BCMA have transformed MM management, albeit access in low- and middle-income countries...
Safety and efficacy of the use of anabolic bone agents in patients with underlying plasma cell dyscrasias: A case series.
Abstract Introduction: Patients with underlying plasma cell dyscrasias (PCD) such as monoclonal gammopathy of undetermined significance (MGU...
Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma
Abstract Background: Brentuximab Vedotin (BV) has demonstrated significant efficacy and favorable safety profile in patients with relapsed o...
Survival outcomes in tickborne infection-associated hemophagocytic lymphohistiocytosis treated with antibiotics alone versus antibiotics and HLH-directed therapy: A multicenter real-world study
Abstract Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome marked by excessive i...
Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies
Abstract Background: STAT5 is a critical mediator of cytokine signaling downstream of tyrosine kinases. STAT5B activating mutations – especia...
Overexpression of CD103 on regulatory T cells mitigates acute graft-versus-host disease via promotion of tolerogenic dendritic cell networks
Abstract Background: Integrin αE (CD103) has been thought to mediate gut-homing Treg retention during GVHD by facilitating E-cadherin intera...
Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma
Abstract INTRODUCTION The German Hodgkin Study Group (GHSG) HD21 trial for adult patients with newly diagnosed advanced-stage classical Hodg...
Toward risk-adjusted hematologic surveillance for telomere biology disorders
Abstract Telomere biology disorders (TBDs) are a heterogeneous group of diseases caused by inherited defects in telomere maintenance, which...
Real-world treatment patterns and outcomes of switching to efanesoctocog alfa in children with severe and moderate haemophilia a: A single-centre experience from the United Arab Emirates
Abstract Background: Haemophilia A management has advanced significantly with the introduction of extended half-life (EHL) recombinant facto...
Burden of chronic obstructive pulmonary disease among patients with hematological malignancies: A nationwide analysis of trends and outcomes
Abstract Introduction: Due to common risk factors such as smoking history and pulmonary toxicities from therapy, chronic obstructive pulmona...
Etoposide can be safely removed from induction chemotherapy without impacting survival for pediatric acute myeloid leukemia – a report from the Children's oncology group study AAML1831
Abstract Introduction: Cytarabine, daunorubicin and etoposide have been the standard backbone of induction chemotherapy...